Expert Discusses Biosignature Model's Potential in Predicting Therapy Response in Early-Stage Breast Cancer

Troy Bremer, PhD, chief ocientific Officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

Related Keywords

Troy Bremer , ,Chief Science ,